Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treati ...

The agency announced on November 2, 2011 that it had approved Edwards Lifesciences' first-generation Sapien TAVR device for patients with severe aortic stenosis who are ineligible for open-heart ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

TAVR is a dynamic field ... we did a first-in-human trial of a transcatheter mitral valve replacement device. Now there are more than 20 mitral valve replacement devices in clinical trials ...

The Transcatheter Aortic Valve Replacement Market primarily revolves around devices designed for minimally invasive valve replacement procedures, which are increasingly preferred over traditional open ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

In particular, research on Edwards' market-leading Sapien TAVR device suggests that the learning curve is 200 cases. That's the inflection point where the physician can deliver optimal patient ...

The firm recently retrenched in the transcatheter aortic valve market after discontinuing its Lotus device. Though we're not particularly optimistic about its new Acurate Neo TAVR franchise ...

The STS used recent national data from the STS Adult Cardiac Surgery Database between 2012 and 2023 to analyze outcomes of SAVR after previous TAVR. The analysis of 5,457 patients reported an ...